{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.4","upperLimit":"121.2","value":"70.93"},{"groupId":"OG001","lowerLimit":"3.3","upperLimit":"23.7","value":"9.26"}]}],"title":"Baseline FSH"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.3","upperLimit":"105.3","value":"74.07"},{"groupId":"OG001","lowerLimit":"27.9","upperLimit":"114.9","value":"70.51"}]}],"title":"Week 24 FSH"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"To describe patterns of FSH levels over the twenty-four week study period.","dispersionType":"Full Range","groups":[{"description":"This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.","id":"OG000","title":"Letrozole"},{"description":"This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.","id":"OG001","title":"Anastrozole"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Change in FSH Levels Baseline to Week 24","type":"SECONDARY","unitOfMeasure":"mIU/ml"}